While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.